Frank Sinner, Vice President Regulatory & Strategic Affairs at HEALTH - Institute of Biomedicine and Health Sciences, introduces OFM in a new video interview series, highlighting projects and services in the area of dermal research. Read more
Dr. Joanna Hummer and Dr. Florie Le Prieult share insights into cOFM's use and utility in the broader neuroscience field and specifically for the development of drugs for neurodegenerative diseases.
The European-funded project Smart-4-Fabry has been conceived to obtain a new nanoformulation of GLA enzyme using nanocapsules, that will improve the toleration and efficacy compared to the current enzyme replacement treatment with non-formulated GLA. The innovation aims to achieve a significant reduction of the actual high cost of Fabry disease treatment and an improvement in the quality of life of Fabry disease patients. Join the final project workshop on 03-FEB-2021. Details and more information about the project under https://smart4fabry.eu
We are pleased to announce that we have prepared some useful content from our Webinar "Informed decisions in dermal drug development with dOFM". Please find below a collection of valuable insights, a comprehensive Q&A Catalogue and easy access to all relevant resources. Browse through a collection of questions raised by our listeners during the live webinar to see which topics are particularly relevant for our audience. Take a more detailed look at the slides and download the presentation including some additional notes from our dOFM experts.
The U.S. Food and Drug Administration recently published a video showing the potential of dermal open-flow microperfusion (dOFM) for generic drug development. FDA approval for most topical generic drugs requires a clinical endpoint study to compare the therapeutic effect with the original product. JOANNEUM RESEARCH HEALTH has developed a new method and strategy (dOFM) to apply for the approval of generic drugs without the need of a clinical endpoint study. Now, the FDA has released a short video illustrating the use of dOFM to evaluate bioequivalence for topical drugs.
In the latest issue of the Journal MABS, Florie Le Prieult and colleagues from AbbVie Germany published latest results they observed after measuring concentrations of a monoclonal anitbody - trastuzumab - in the interstitial brain fluid (ISF) of awake and freely moving mice. The only currently available methods for extracting ISF, are Microdialysis (MD) and cerebral open flow microperfusion (cOFM). For the first time, both methods were compared at a technical and performance level for the collection of large molecules in rodents. They found 10-fold higher absolute concentrations in cOFM samples compared to MD. In vivo recovery revealed an increased extraction of trastuzumab at low flow rates and a 6-fold higher absolute concentration at steady state than initially calculated with the in vitro recovery. The authors conclude that the “standardization of these complex methods makes the unraveling of ISF concentrations attainable for various diseases and modalities, starting in this study with mAbs, but extending further in the future to RNA therapeutics, antibody-drug conjugates, and even cell therapies.”